Organon & Co. (NYSE:OGN) Hits New 12-Month Low – Time to Sell?

Shares of Organon & Co. (NYSE:OGN) reached a new 52-week low during trading on Tuesday . The stock traded as low as $10.45 and last traded at $10.67, with a volume of 4492118 shares trading hands. The stock had previously closed at $11.12.

Wall Street Analyst Weigh In

Several brokerages have weighed in on OGN. Morgan Stanley cut their price target on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 9th. TD Cowen raised shares of Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. Finally, Barclays cut their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Friday, February 14th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.60.

Organon & Co. Trading Down 4.0 %

The stock has a market capitalization of $2.75 billion, a PE ratio of 3.20, a P/E/G ratio of 0.90 and a beta of 0.73. The company’s 50 day moving average price is $14.17 and its two-hundred day moving average price is $15.32. The company has a debt-to-equity ratio of 17.73, a current ratio of 1.70 and a quick ratio of 1.21.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.83 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date was Monday, February 24th. This represents a $1.12 dividend on an annualized basis and a yield of 10.50%. Organon & Co.’s dividend payout ratio is currently 33.63%.

Hedge Funds Weigh In On Organon & Co.

Several large investors have recently made changes to their positions in OGN. Pacer Advisors Inc. lifted its stake in Organon & Co. by 94,482.1% during the fourth quarter. Pacer Advisors Inc. now owns 11,152,179 shares of the company’s stock worth $166,391,000 after purchasing an additional 11,140,388 shares in the last quarter. Norges Bank purchased a new position in shares of Organon & Co. in the fourth quarter valued at approximately $25,258,000. Magnetar Financial LLC grew its holdings in shares of Organon & Co. by 560.2% in the fourth quarter. Magnetar Financial LLC now owns 1,734,434 shares of the company’s stock valued at $25,878,000 after purchasing an additional 1,471,731 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Organon & Co. in the 4th quarter valued at approximately $11,892,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Organon & Co. by 23.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company’s stock worth $48,999,000 after acquiring an additional 629,191 shares during the period. 77.43% of the stock is currently owned by institutional investors and hedge funds.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.